Breakfast C-Level Panel Discussion: Overcoming Challenges in the Field & Current Thoughts on Progress

Time: 9:00 am
day: Day Two


  • Thinking outside the box when it comes to disease indications to identify and prioritize for inflammasome therapeutic success
  • Balancing commercial considerations of drug development with unmet need across diseases
  • How crucial is it to demonstrate differentiation from standards of care or other inflammasome inhibitors?
  • Should you plan for comparative data with standards of care in preclinical models before selecting indications and comparing across modalities?
  • Exploring the deals in the space: How to raise capital, attract investors and large pharma interest
  • Thoughts on evidence that activation of more than one type of NLR act is pathogenic – are people going to take different directions to drug development now?